The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Uday Kompella Biography and Net Worth

Director of Ocugen

Dr. Kompella is an Ocugen Co-founder and a member of the board. He is a Professor of Pharmaceutical Sciences, Ophthalmology, and Bioengineering at University of Colorado-Anschutz Medical Campus, with research interests in the areas of drug discovery, drug delivery, and nanotechnology for treating a variety of degenerative, neovascular, and inflammatory disorders including retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, and cancers. Dr. Kompella is a Fellow of the American Association of Pharmaceutical Scientists (AAPS) and the Association for Research in Vision and Ophthalmology (ARVO) and serves as the Editor-in-Chief for the journal Expert Opinion on Drug Delivery. Also, he is an editor for the journals, Pharmaceutical Research and the Journal of Ocular Pharmacology and Therapeutics. Dr. Kompella is a recipient of the Distinguished Scientist Award (University of Nebraska Medical Center), Distinguished Teacher Award (University of Nebraska Medical Center), and Dean’s Mentoring Award (University of Colorado Anschutz Medical Campus). He is also a recipient of the ARVO Foundation for Eye Research/Pfizer Ophthalmics/Carl Camras Translational Research Award in Ophthalmology. Dr. Kompella obtained his PhD in Pharmaceutical Sciences from the University of Southern California.

What is Uday Kompella's net worth?: The estimated net worth of Uday Kompella is at least $508,755.59 as of July 30th, 2021. Dr. Kompella owns 560,674 shares of Ocugen stock worth more than $508,756 as of November 23rd. This net worth estimate does not reflect any other investments that Dr. Kompella may own. Additionally, Dr. Kompella receives a salary of $60,000.00 as Director at Ocugen. Learn More about Uday Kompella's net worth.
How old is Uday Kompella?: Dr. Kompella is currently 57 years old. There are 4 older executives and no younger executives at Ocugen. The oldest executive at Ocugen is Dr. Shankar Musunuri M.B.A., Ph.D., Co-Founder, CEO & Chairman, who is 60 years old. Learn More on Uday Kompella's age.
What is Uday Kompella's salary?: As the Director of Ocugen, Inc., Dr. Kompella earns $60,000.00 per year. There are 3 executives that earn more than Dr. Kompella. The highest earning executive at Ocugen is Dr. Shankar Musunuri M.B.A., Ph.D., Co-Founder, CEO & Chairman, who commands a salary of $864,250.00 per year. Learn More on Uday Kompella's salary.
How do I contact Uday Kompella?: The corporate mailing address for Dr. Kompella and other Ocugen executives is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. Ocugen can also be reached via phone at (484) 328-4701 and via email at [email protected]. Learn More on Uday Kompella's contact information.
Has Uday Kompella been buying or selling shares of Ocugen?: Uday Kompella has not been actively trading shares of Ocugen during the last ninety days. Most recently, Uday Kompella sold 25,000 shares of the business's stock in a transaction on Monday, November 1st. The shares were sold at an average price of $14.05, for a transaction totalling $351,250.00. Learn More on Uday Kompella's trading history.
Who are Ocugen's active insiders?: Ocugen's insider roster includes Kirsten Castillo (Director), Prabhavathi Fernandes (Director), Uday Kompella (Director), Ramesh Kumar (Director), Shankar Musunuri (CEO), Manish Potti (Director), Sanjay Subramanian (CFO), Vijay Tammara (SVP), and Junge Zhang (Director). Learn More on Ocugen's active insiders.

Uday Kompella Insider Trading History at Ocugen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/1/2021	Sell	25,000	$14.05	$351,250.00
10/25/2021	Sell	46,371	$9.08	$421,048.68
10/20/2021	Sell	1,731	$9.02	$15,613.62
10/18/2021	Sell	200,000	$8.41	$1,682,000.00
7/30/2021	Sell	10,000	$6.81	$68,100.00	560,674
6/25/2021	Sell	10,000	$8.13	$81,300.00	560,674
5/28/2021	Sell	7,191	$8.82	$63,424.62	557,865
5/3/2021	Sell	50,000	$15.01	$750,500.00	620,674
4/30/2021	Sell	20,000	$11.56	$231,200.00	620,674
4/26/2021	Sell	350,000	$11.70	$4,095,000.00	600,674

Uday Kompella Buying and Selling Activity at Ocugen

Ocugen Company Overview

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Today's Range

Now: $0.91

$0.89

$0.93

50 Day Range

MA: $0.98

$0.87

$1.17

2 Week Range

Now: $0.91

$0.36

$2.11

Volume

2,462,390 shs

Average Volume

4,341,110 shs

Market Capitalization

$264.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.75

Financial Prophecy

From Porter & Company | Ad